Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPSE | Q9Y251 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5834648 | 0.94 | HPSE (1.00) | HPSE | |
| SCHEMBL5834620 | 0.94 | HPSE (0.88) | HPSE | |
| SCHEMBL5834945 | 0.93 | HPSE (1.00) | HPSE | |
| SCHEMBL5835624 | 0.93 | HPSE (1.00) | HPSE | |
| SCHEMBL5835042 | 0.92 | HPSE (1.00) | HPSE | |
| SCHEMBL5835005 | 0.92 | HPSE (0.85) | HPSE | |
| SCHEMBL5834278 | 0.90 | HPSE (1.00) | HPSE | |
| SCHEMBL5834535 | 0.90 | HPSE (1.00) | HPSE | |
| SCHEMBL5834879 | 0.89 | HPSE (1.00) | HPSE | |
| SCHEMBL5834822 | 0.89 | HPSE (0.95) | HPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023175581-A1 | HEPARANASE INHIBITION FOR GRAFT PROTECTION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-21 | — | — | WO | claimed |
| US-7138425-B2 | Phthalimide carboxylic acid derivatives | OXFORD GLYCOSCIENCE (UK) LTD. (GB) | 2006-11-21 | — | — | US | claimed |
| US-20050203153-A1 | Phthalimide carboxylic acid derivatives | OXFORD GLYCOSCIENCE (UK) LTD. (GB) | 2005-09-15 | — | — | US | claimed |
| WO-2023175581-A1 | HEPARANASE INHIBITION FOR GRAFT PROTECTION | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20200093852-A1 | Methods of Treating Ocular Disorders | Beta Therapeutics Pty Ltd (AU) | 2020-03-26 | — | — | US | disclosed |
| US-7138425-B2 | Phthalimide carboxylic acid derivatives | OXFORD GLYCOSCIENCE (UK) LTD. (GB) | 2006-11-21 | — | — | US | disclosed |
| US-20050203153-A1 | Phthalimide carboxylic acid derivatives | OXFORD GLYCOSCIENCE (UK) LTD. (GB) | 2005-09-15 | — | — | US | disclosed |
| EP-1483261-A1 | PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES | Oxford GlycoSciences (UK) Ltd, Attn: Mary Gadsden (GB) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074516-A1 | PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES | OXFORD GLYCOSCIENCES (UK) LTD (GB) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203153-A1 | Phthalimide carboxylic acid derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, IDH1 | HPSE 2626/4885 |
| US-20200093852-A1 | Methods of Treating Ocular Disorders | ALDH1A2, HPSE, RB1 | HPSE 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.